The time from breast cancer diagnosis to the first delivery was significantly higher among women who received endocrine treatment (5.3 ± 2.5 years versus 3.1 ± 1.5 years, p = 0.0003) and among those who received anti-Her2 targeted therapy (4.9 ± 2.1 years versus 3.6 ± 2.1 years, p = 0.04) compared to BC patients without this certain treatment (Figure 1). This evidence concerns the gene ERBB2 and breast carcinoma.